Health Care & Life Sciences » Biotechnology | Bavarian Nordic A/S

Bavarian Nordic A/S | Income Statement

Fiscal year is January-December. All values DKK Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,213
1,217
1,021
1,007
1,370
500
Cost of Goods Sold (COGS) incl. D&A
497
506
425
303
366
267
Gross Income
715
711
596
704
1,005
233
SG&A Expense
680
694
594
670
654
589
EBIT
36
17
2
34
351
355
Unusual Expense
7
6
3
24
25
22
Non Operating Income/Expense
25
70
67
17
90
12
Interest Expense
5
4
3
4
6
15
Pretax Income
6
64
78
40
302
357
Income Tax
53
38
18
9
121
5
Consolidated Net Income
47
26
59
31
181
362
Net Income
47
26
59
31
181
362
Net Income After Extraordinaries
47
26
59
31
181
362
Net Income Available to Common
47
26
59
31
181
362
EPS (Basic)
1.80
1.00
2.10
1.00
5.70
11.22
Basic Shares Outstanding
26
26
28
30
32
32
EPS (Diluted)
1.79
0.98
2.08
1.01
5.69
11.22
Diluted Shares Outstanding
26
26
29
30
32
32
EBITDA
80
62
48
78
458
314
Non-Operating Interest Income
7
4
15
16
21
23

About Bavarian Nordic A/S

View Profile
Address
Hejreskovvej 10A
Kvistgaard CR 3490
Denmark
Employees -
Website http://www.bavarian-nordic.com
Updated 07/08/2019
Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases.